Associations among inflammatory cytokines, erythropoietin (EPO), and anemia in critically ill septic patients remain unclear. This study tested the hypothesis that elevated inflammatory cytokines and decreased EPO would be associated with iron-restricted anemia while accounting for operative blood loss, phlebotomy blood loss, and red blood cell (RBC) transfusion volume.
A
nemia affects approximately 95% of all patients who remain critically ill for 3 or more days. 1 Management of severe anemia often involves red blood cell (RBC) transfusion, which places patients at increased risk for infectious complications and mortality. Etiologies of anemia among intensive care unit (ICU) patients include decreased RBC survival, blood loss, dysregulated iron metabolism, and bone marrow suppression. [2] [3] [4] [5] Increased erythropoietin (EPO) production is an important compensatory mechanism, promoting erythropoiesis in response to anemia and hypoxic stress. Exogenous EPO administration has been investigated as therapeutic strategy for the management of critically ill anemic subjects, with mixed results in large randomized trials. 6, 7 Sepsis is associated with increased circulating EPO levels compared with healthy control values, but ICU patients have a smaller increase in EPO than healthy subjects with the same degree of anemia, implicating a blunted EPO response in the pathophysiology of anemia of critical illness.
Several cytokines affect erythropoiesis and EPO physiology. Interleukins 6 and 8 (IL-6 and IL-8) influence erythropoiesis by modulating hepcidin and iron metabolism. Exogenous granulocyte colony-stimulating factor (G-CSF) potentiates anemia among breast cancer patients receiving adjuvant chemotherapy, and elevated G-CSF is associated with persistent anemia following severe traumatic injury in rats and humans. [8] [9] [10] Plasma stromal cell-derived factor 1 (SDF-1; also known as CXCL12) is elevated following traumatic injury in rodents and humans and promotes mobilization of hematopoietic progenitors from the bone marrow to sites of injury. 11, 12 In vitro and in vivo models have implicated the inflammatory cytokine tumor necrosis factor (TNF) α in suppression of EPO and erythropoiesis. 13, 14 These cytokines have the propensity to promote iron-restricted erythropoiesis, characterized by functional rather than absolute iron deficiency, occurring secondary to dysregulation of iron metabolism and trafficking.
Associations among inflammatory cytokines, EPO, and anemia in critically ill septic patients remain unclear. Analysis of these associations in critically ill patients is confounded by the effects of operative blood loss (OBL), phlebotomy blood loss (PBL), and RBC transfusions on hemoglobin (Hb) levels. The purpose of this study was to investigate associations among IL-6, IL-8, and G-CSF, SDF-1, TNF-α, and EPO on anemia among critically ill septic patients. We hypothesized that high levels of inflammatory cytokines and decreased EPO would be associated with persistent anemia among critically ill septic patients when adjusting Hb levels for the effects of OBL, PBL, and RBC transfusions and that critically ill septic patients would exhibit an iron-restricted anemia phenotype.
METHODS
We performed a prospective observational cohort analysis of 42 adult (age, ≥18 years) patients treated for sepsis, as defined below, in our surgical ICUs. This study was registered on ClinicalTrials.gov (NCT02276417). Institutional review board approval was obtained. All study subjects signed written informed consent. Patients were identified by a modified version of the Modified Early Warning Score early-detection protocol, which screened for sepsis based on temperature, heart rate, respiratory rate, blood pressure, and level of consciousness. 15 Patients identified by this screening protocol were then assessed for the presence of severe sepsis (sepsis-induced tissue hypoperfusion or organ dysfunction) or septic shock (severe sepsis with persistent arterial hypotension despite volume resuscitation) based on consensus definitions. [16] [17] [18] Resuscitation and management strategies were standardized according to a computerized clinical decision support protocol. 19, 20 Patients with unmeasured blood loss (e.g., traumatic injury, gastrointestinal bleeding, and postoperative hemorrhage) were excluded. Patients with total hospital length of stay less than 14 days were excluded to ensure that data would not be censored because of patient discharge. Additional exclusion criteria were age less than 18 years, transfer following outside facility length of stay more than 2 days, severe traumatic brain injury (computed tomography evidence of neurologic injury and Glasgow Coma Scale score of <8), spinal cord injury resulting in permanent sensory and/or motor deficits, sepsis with an uncontrollable source (e.g., unresectable bowel ischemia), NY Heart Association class IV heart failure, Child-Pugh Class B or C liver disease, known human immunodeficiency virus infection with CD4 count of less than 200 cells/mm 3 , organ transplant recipient on an immunosuppressant agent, administration of exogenous EPO within 30 days before onset of sepsis or during admission, chemotherapy or radiotherapy within 30 days before onset of sepsis, expected lifespan of less than 3 months because of severe preexisting comorbidities, active do not resuscitate or do not intubate order, pregnancy, incarceration, or institutionalization.
Data regarding baseline patient characteristics, management, and outcomes for each study subject were collected and managed using the REDCap electronic data capture platform (REDCap, Nashville, TN). For all parameters, time zero was recognition of sepsis and initiation of the computerized clinical decision support protocol. Plasma IL-6, IL-8, G-CSF, SDF-1, TNF-α, and EPO levels were determined by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) and Luminex (Merck Millipore, Darmstadt, Germany and Luminex Corporation, Madison, WI) performed on samples obtained within 12 hours and on days 1, 4, 7, and 14. Hemoglobin and mean corpuscular volume (MCV) were measured at the same time points. Mean corpuscular volume was included in the analysis because unlike many other biomarker used in this study, MCV is measured on standard complete blood count laboratory tests and therefore readily available to clinicians. Among healthy subjects, MCV equilibrates within approximately 6 hours of RBC transfusion. Serum transferrin receptor (sTfR) levels were measured by enzyme-linked immunosorbent assay (R&D Systems) within 12 hours and on day 14. Unlike ferritin, soluble transferrin receptor is not an acute-phase reactant and may be the most reliable marker of iron deficiency during critical illness. Serum transferrin receptor increases during iron deficiency anemia and remains normal during anemia due to inflammation. 21, 22 Serum iron was not measured because its diagnostic utility is limited by variability in protein-binding properties and bioavailability during inflammatory states. 23 Adjusted ΔHb was calculated as previously described. 24 Hemoglobin levels at sepsis onset and hospital discharge were used to calculate change in Hb (ΔHb) from sepsis onset to hospital discharge for each patient. To account for the effects of OBL, PBL, and PRBC transfusions on Hb levels, each of these variables was recorded for each patient. To estimate PBL, the amount of blood drawn for each commonly performed laboratory test was determined. At our institution during the study period, basic metabolic panels and complete blood counts contained 5 to 7 mL of blood, arterial blood gases contained 2 mL of blood, and blood cultures contained 8 to 10 mL of blood. Next, the number of laboratory tests performed daily for ICU and floor patients and associated PBL was ascertained from previous reports.
3,25-27 Based on these parameters, PBL was calculated by multiplying the first 30 ICU days by 55 mL/d, multiplying all additional ICU days by 13 mL/d, multiplying the number of ICU-free days by 9 mL/d, and adding these three values. Operative blood loss was obtained from operative notes in the electronic health record. At our institution, general indications for red cell transfusion are Hb level of less than 7 g/dL or hematocrit level of less than 21% for patients with no symptomatic cardiovascular disease, Hb level of less than 10 g/dL or hematocrit level of less than 30% for patients with symptomatic cardiovascular disease, and acute blood loss of greater than 30% of total blood volume. Operative blood loss, PBL, and PRBC transfusion volume were recorded in milliliters. Each 300 mL change in blood volume was expressed as a 1 g/dL change in Hb (e.g., 600 mL blood loss = Hb decrease by 2 g/dL, 900 mL PRBC transfusion = Hb increase by 3 g/dL) based on previous work. [28] [29] [30] [31] ΔHb was then adjusted to account for the effects of OBL, PBL, and PRBC transfusion volume.
Statistical analysis and figure production were performed in SPSS (version 24, IBM, Armonk, NY) and GraphPad Prism (version 6.05; GraphPad Software, La Jolla, CA). A power analysis was not performed, as this was an exploratory study. Base deficit and pH values were missing at random for one patient (5%). Base deficit and pH were analyzed using the available data without imputing missing values. Missing data and outliers identified by the ROUT method for each plasma and serum analyte at each time point are illustrated in Supplemental Table (Table, Supplemental Digital Content 1, http://links.lww.com/TA/B246). Continuous variables were compared by the Kruskal-Wallis test and reported as median (interquartile range). Discrete variables were compared by Fisher exact test and reported as n (%). Linear regression was performed to assess relationships between day 14 cytokine levels, and adjusted ΔHb (AdjΔHb) was reported as r 2 coefficients. Significance was set at α = 0.05.
RESULTS
Forty-two patients were included. The study population had advanced age (65 years) and a substantial burden of chronic disease (Charlson comorbidity index, 4.5) ( Table 1 ). The most common primary diagnosis was intra-abdominal sepsis, affecting half of the study population. Comparing patients with positive (+) versus negative (−) AdjΔHb, there were no significant differences in age, sex, chronic disease burden, primary diagnosis, or Acute Physiology and Chronic Health Evaluation II scores at the time of sepsis onset. However, patients with −AdjΔHb had significantly lower core body temperature (36.9°C vs. 37.4°C, p = 0.032) at the time of sepsis onset.
Management and outcome parameters are listed in Table 2 . Sixty-seven percent of all patients required a source control procedure, without significant differences between cohorts. Operative blood loss, PBL, and RBC transfusion burden were not significantly different between cohorts, although discharge Hb was significantly lower in the −AdjΔHb cohort (8.4 vs. 9.3 g/dL, p = 0.001). There were two patients in the −AdjΔHb group who developed new dialysis requirements during admission and no patients in the +AdjΔHb group who developed new dialysis requirements (p = 0.247). Median hospital length of stay was 23 days, with 13 of these days spent in the ICU, and no significant differences between cohorts. Only 15 (36%) of 42 patients were discharged to their home. There was one inpatient mortality (2%), which occurred in the −AdjΔHb cohort. The strongest associations between cytokine levels and AdjΔHb occurred on day 14, as illustrated in Figure 1 . Patients with −AdjΔHb had higher day 14 levels of IL-8 (39.1 vs. 18.2 pg/mL, p = 0.01) and G-CSF (101.3 vs. 60.5 pg/mL, p = 0.01). The −AdjΔHb cohort also had higher levels of day 14 TNF-α (22.8 vs. 13.5 pg/mL), although the difference was not statistically significant (p = 0.12). Day 14 EPO was similar between −AdjΔHb and +AdjΔHb cohorts (27.1 vs. 38.5 mIU/ mL, respectively, p = 0.79).
Linear regression was performed to assess the relationship between day 14 cytokine levels and AdjΔHb as a continuous variable, as illustrated in Figure 2 . Lower AdjΔHb was associated with higher day 14 levels of IL-6 (r 2 = 0.22, p < 0.01), IL-8 (r 2 = 0.10, p = 0.04), SDF-1 (r 2 = 0.14, p = 0.02), and TNF-α (r 2 = 0.13, p = 0.02). However, there was no significant relationship between day 14 EPO and AdjΔHb (r 2 = 0.08, p = 0.08). Analysis of MCVand sTfR is illustrated in Figure 3 . Mean corpuscular volume was initially similar between cohorts but was significantly lower among patients with −AdjΔHb on days (Fig. 3A) . Serum transferrin receptor levels were similar between cohorts at the time of sepsis protocol initiation and on day 14 (Fig. 3B) .
DISCUSSION
In this study, persistent inflammation following septic insult was associated with persistent anemia, independent of EPO levels. Patients with −AdjΔHb developed a microcytic anemia, implicating inflammatory iron-restricted erythropoiesis. Serum transferrin receptor was not significantly different between cohorts, indicating that systemic iron deficiency may not have been responsible for the observed microcytic anemia. Although most clinical parameters were similar between patients with +AdjΔHb and −AdjΔHb, core body temperature at the time of sepsis onset was significantly lower in patients with −AdjΔHb. Hypothermia has been previously associated with impaired erythropoiesis in animal and human studies. [32] [33] [34] Although the difference in red cell transfusions between groups Figure 2 . Cytokines that influence erythropoiesis measured in plasma 14 days after recognition of sepsis an initiation of a standardized treatment protocol. Initial and discharge Hb were used to calculate ΔHb. Operative blood loss, PBL, and RBC transfusion volume were used to calculate AdjΔHb assuming that 300 mL RBC is equal to 1 g/dL Hb. Linear regression was performed to calculate r
was not statistically significant, this may represent a falsenegative analysis attributable to small group sizes. Receipt of 1.0 unit versus 2.5 units of red cells impacts iron availability because of the relatively high concentrations of iron in red cell transfusions and impacts cytokine profiles. The observation that MCV was lower among subjects with −AdjΔHb despite receiving more red cell transfusions supports the hypothesis that anemia among septic patients is partially attributable to functional iron restriction. Previous studies have established correlations between inflammatory cytokines and erythropoiesis. Wu et al. 35 demonstrated that plasma from severely injured patients suppresses hematopoietic progenitor cell growth in bone marrow from healthy subjects. The effects appeared to be mediated by the bone marrow stroma, consistent with in vitro studies by Fonseca et al. 35, 36 These effects also occurred early after injury and resolved quickly, suggesting that homeostasis was restored early following hemorrhage control and tissue repair, in contrast to the persistent inflammation often associated with sepsis. In vivo studies by Schubert et al. 37 have demonstrated that anemia develops in mice subjected to septic peritonitis by cecal ligation and puncture in both TNF-deficient and wild-type mice, suggesting that anemia following septic insult may not be mediated by TNF-α. However, several other in vitro and in vivo models have implicated TNF-α in suppression of erythropoiesis, consistent with our observations. 13, 14 Interleukins 6 and 8 may hinder erythropoiesis by modulating hepcidin and iron metabolism. The microcytic erythrocyte phenotype observed in our study is consistent with this hypothesis. Exogenous administration of G-CSF to breast cancer patients receiving adjuvant chemotherapy has been shown to worsen anemia in a dose-dependent manner. 8 This effect may have been due to mobilization of erythrocyte progenitors from the bone marrow to the peripheral blood, a phenomenon that has been described among severely injured rodents and critically ill trauma patients. 8, 10 Although use of G-CSF for septic patients with neutropenia is widely reported, associations between G-CSF and anemia among septic patients are not well defined.
The lack of correlation between EPO and persistent anemia in the present study may be because of blunting of the EPO response, which has been described during critical illness and sepsis. Several clinical trials have evaluated the efficacy of exogenous EPO for critically ill patients. However, the appropriate role of exogenous EPO in this setting remains controversial. In a large randomized multicenter trial (n = 1,302), exogenous EPO increased Hb levels and decreased RBC transfusion among critically ill patients. 6 A subsequent trial of similar design (n = 1,460) substantiated the effects of EPO on Hb concentration but did not detect a difference in RBC transfusion requirements. 7 Despite a significant increase in thrombotic events among patients receiving EPO in the second trial, which may have been impacted by inconsistent provision of chemoprophylaxis for venous thromboembolic disease, both demonstrated survival advantages among trauma subpopulations. This finding may be attributable to nonhematologic properties of EPO, including anti-inflammatory properties and cytoprotective effects on apoptosis. However, a meta-analysis of nine randomized trials of EPO administration to a broader population of critically ill patients did not identify a significant decrease in mortality with exogenous EPO (odds ratio, 0.81; 95% confidence interval, 0.61-1.01). 38 In addition, inhibition of the EPO receptor (EPO-R) has been shown to neutralize EPO activity and potentiate anemia. 39 It remains plausible that downregulation of EPO-R is partly responsible for abrogating the beneficial effects of EPO among critically ill septic patients. Our findings suggest that EPO may not play a central role in the pathophysiology of anemia among critically ill septic patients.
This study was limited by a small number of subjects (n = 42), heterogeneous patient population, and limited generalizability due to single-institution design. Fortunately, the observed associations between cytokines and hematologic parameters were strong enough that significant effects were observed in this small sample, which would have been underpowered to detect subtle differences. However, analyses that were not statistically significant may represent type II errors with false-negative findings and should be interpreted with caution. Future investigations of anemia among critically septic patients should include patients who are not subjected to ongoing inflammation due to surgical procedures and should include assessment of EPO-R and hepcidin physiology as well as the presence of iron-deficient erythropoiesis by assessment of erythrocyte zinc protoporphyrin levels. 40, 41 A deeper understanding of the pathophysiology of anemia among critically ill septic patients may promote the development and implementation of preventative and therapeutic measures targeting iron restriction secondary to persistent inflammation and dysregulated trafficking of available iron stores. Further investigation of the pathophysiology of this condition is especially important given the inconsistent results from trials of iron supplementation and hepcidin antagonism for abrogating anemia among critically ill patients. Because both anemia and red cell transfusion are associated with significantly increased risk for adverse events, mitigating anemia without the need for transfusion harbors the potential to improve outcomes among septic patients.
CONCLUSION
Among critically ill patients, persistent inflammation following septic insult was associated with microcytic anemia in the absence of systemic iron deficiency, independent of endogenous plasma EPO. These effects were observed while accounting for the effects of OBL, PBL, and RBC transfusions. Future research should focus on the roles of EPO-R and hepcidin in the pathophysiology of anemia among critically ill septic patients.
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